Coronado Biosciences, Inc. (NASDAQ:CNDO) announced that Dr. Eric Hollander, Clinical Professor of Psychiatry and Behavioral Sciences at Albert Einstein College of Medicine of Yeshiva University and Director of the Autism and Obsessive Compulsive Spectrum Program at Montefiore Medical Center and Einstein, presented interim data from his pilot study of oral TSO (Trichuris suis ova or CNDO-201) to treat autism at the American College of Neuropsychopharmacology Annual Meeting in Hollywood, Florida Coronado Biosciences Inc (NASDAQ:CNDO) stock in last trading day opened at $3.07, traded the day range of $2.70 – $3.15 and closed at $2.75. The stock showed a negative performance of -9.54% in previous trading session.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) ended six-day rally, possibly on profit taking. The company is expected to release topline data from its Phase IIb IBS-C trial in the first quarter 2014 and insiders have also been buying Synergy stock this year, providing signs where the stock will be going in the future and it is encouraging to see them start to put their money behind the company before data release.In last trading activity, Progenics Pharmaceuticals, Inc.(NASDAQ:PGNX) traded 60.83 million shares and the average volume of the stock was recorded as 854,477.00 shares. The 52 week range of the stock is $5.33 – $5.82. The stock was dropped -5.80% by closing at $5.30.
XOMA Corporation (NASDAQ:XOMA) is engaged in the discovery and development of antibody-based therapeutics. XOMA Corp (NASDAQ:XOMA) stock on December 27, 2013, recorded a fall of -5.34% and was in a range of $6.75 – $7.33 before closing at $6.91. Company’s 52-week low price is $2.37 and 52 week high price is $7.45.
“Last Friday, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that the FDA approved the revised label for Iclusig, which is now indicated for the treatment of adult patients with either T315I mutation or chronic phase, accelerated phase, or blast phase CML or Ph+ ALL patients for whom no other tyrosine-kinase inhibitor therapy is indicated. The starting dose of Iclusig remains at 45 mg/day. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares fell -5.14% in last trading session and was closed at $6.64, while trading in range $of 6.51 -$ 6.92. Its return on equity ratio is recorded as -100.20% and its return on assets is -70.60%.
Geron Corporation (NASDAQ:GERN) company announced that management hosted a live webcast of an analyst and investor meeting at 6:30 p.m. CT on December 9, 2013. John A. Scarlett, M.D., Geron`s President and Chief Executive Officer, will discuss the data presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition from the investigator-sponsored study (IST) of imetelstat in myelofibrosis being conducted at Mayo Clinic, Rochester, MNGeron Corporation (NASDAQ:GERN) stock in last trading day opened at $5.08, traded the day range of $4.83 – $5.08, and closed at $4.84. The stock showed a negative performance of 4.84% in previous trading session.